Meeting
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
Authors
Cheng Wang
Southwest Hospital, Army Medical University, Chongqing, China
Cheng Wang , Rui Wang , Guozhi Zhang , Andi Wan , Siyi Xiong , Long Yuan , Hao Tian , Dandan Ma , Jun Jiang , Yi Zhang , Xiaowei Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
ChiCTR1900023776
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 593)
DOI
10.1200/JCO.2023.41.16_suppl.593
Abstract #
593
Poster Bd #
423
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring
Poster
2021 ASCO Annual Meeting
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
First Author: Fangchao Zheng
Poster
2021 ASCO Annual Meeting
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
First Author: Ignacio Ortego
Poster
2018 ASCO Annual Meeting
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
First Author: Volker Moebus